Patients receiving cisplatin-based chemotherapy experience a high incidence of thromboembolic events, highlighting an urgent need for randomized trials evaluating prophylactic anticoagulation in this population.
This large retrospective analysis confirms the unacceptable incidence of TEEs in patients receiving cisplatin-based chemotherapy. In view of the controversy associated with prophylactic anticoagulation in patients with cancer treated with chemotherapy, randomized studies are urgently needed in this specific cancer population treated with cisplatin-based regimens.
Moore et al. (2011) studied this question.